Trial Profile
Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Therapeutic Use
- 16 Jan 2024 Study design changed from Crossover Assignment to Parallel Assignment.
- 16 Jan 2024 Status changed from active, no longer recruiting to completed.
- 16 Jun 2023 Primary endpoint (Response Rate) has not been met according to Results published in the Rheumatology.